498 related articles for article (PubMed ID: 17628203)
1. Prodrug strategies to overcome poor water solubility.
Stella VJ; Nti-Addae KW
Adv Drug Deliv Rev; 2007 Jul; 59(7):677-94. PubMed ID: 17628203
[TBL] [Abstract][Full Text] [Related]
2. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
3. Prodrugs: design and clinical applications.
Rautio J; Kumpulainen H; Heimbach T; Oliyai R; Oh D; Järvinen T; Savolainen J
Nat Rev Drug Discov; 2008 Mar; 7(3):255-70. PubMed ID: 18219308
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in intravenous delivery of poorly water-soluble compounds.
Shi Y; Porter W; Merdan T; Li LC
Expert Opin Drug Deliv; 2009 Dec; 6(12):1261-82. PubMed ID: 19941409
[TBL] [Abstract][Full Text] [Related]
5. Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
Müller CE
Chem Biodivers; 2009 Nov; 6(11):2071-83. PubMed ID: 19937841
[TBL] [Abstract][Full Text] [Related]
6. Prodrugs--from serendipity to rational design.
Huttunen KM; Raunio H; Rautio J
Pharmacol Rev; 2011 Sep; 63(3):750-71. PubMed ID: 21737530
[TBL] [Abstract][Full Text] [Related]
7. [Research of oral prodrugs: opportunities and challenges].
Cao F; Ping QN; Chen J
Yao Xue Xue Bao; 2008 Apr; 43(4):343-9. PubMed ID: 18664193
[TBL] [Abstract][Full Text] [Related]
8. Is prodrug design an approach to increase water solubility?
Sanches BMA; Ferreira EI
Int J Pharm; 2019 Sep; 568():118498. PubMed ID: 31301465
[TBL] [Abstract][Full Text] [Related]
9. Designing for topical delivery: prodrugs can make the difference.
Sloan KB; Wasdo S
Med Res Rev; 2003 Nov; 23(6):763-93. PubMed ID: 12939791
[TBL] [Abstract][Full Text] [Related]
10. No auxiliary, no byproduct strategy for water-soluble prodrugs of taxoids: scope and limitation of O-N intramolecular acyl and acyloxy migration reactions.
Skwarczynski M; Sohma Y; Noguchi M; Kimura M; Hayashi Y; Hamada Y; Kimura T; Kiso Y
J Med Chem; 2005 Apr; 48(7):2655-66. PubMed ID: 15801856
[TBL] [Abstract][Full Text] [Related]
11. Do prodrugs deliver?
Smith DA
Curr Opin Drug Discov Devel; 2007 Sep; 10(5):550-9. PubMed ID: 17786853
[TBL] [Abstract][Full Text] [Related]
12. What should be considered on design of a colon-specific prodrug?
Jung Y; Kim YM
Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945
[TBL] [Abstract][Full Text] [Related]
13. Prodrugs of thiabendazole with increased water-solubility.
Nielsen LS; Bundgaard H; Falch E
Acta Pharm Nord; 1992; 4(1):43-9. PubMed ID: 1515051
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone.
Mäntylä A; Rautio J; Nevalainen T; Keski-Rahkonen P; Vepsälainen J; Järvinen T
Eur J Pharm Sci; 2004 Oct; 23(2):151-8. PubMed ID: 15451003
[TBL] [Abstract][Full Text] [Related]
15. O-N intramolecular acyl migration reaction in the development of prodrugs and the synthesis of difficult sequence-containing bioactive peptides.
Sohma Y; Hayashi Y; Skwarczynski M; Hamada Y; Sasaki M; Kimura T; Kiso Y
Biopolymers; 2004; 76(4):344-56. PubMed ID: 15386265
[TBL] [Abstract][Full Text] [Related]
16. Prodrugs: Some thoughts and current issues.
Stella VJ
J Pharm Sci; 2010 Dec; 99(12):4755-65. PubMed ID: 20821387
[TBL] [Abstract][Full Text] [Related]
17. Prodrug strategies in anticancer chemotherapy.
Kratz F; Müller IA; Ryppa C; Warnecke A
ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and pharmacological evaluation of the aqueous prodrugs of desmethyl anethole trithione with hepatoprotective activity.
Chen P; Luo Y; Hai L; Qian S; Wu Y
Eur J Med Chem; 2010 Jul; 45(7):3005-10. PubMed ID: 20392547
[TBL] [Abstract][Full Text] [Related]
19. Orally bioavailable prodrugs of a BCS class 2 molecule, an inhibitor of HIV-1 reverse transcriptase.
Elworthy TR; Dunn JP; Hogg JH; Lam G; Saito YD; Silva TM; Stefanidis D; Woroniecki W; Zhornisky E; Zhou AS; Klumpp K
Bioorg Med Chem Lett; 2008 Dec; 18(24):6344-7. PubMed ID: 18993071
[TBL] [Abstract][Full Text] [Related]
20. Development of novel water-soluble photocleavable protective group and its application for design of photoresponsive paclitaxel prodrugs.
Noguchi M; Skwarczynski M; Prakash H; Hirota S; Kimura T; Hayashi Y; Kiso Y
Bioorg Med Chem; 2008 May; 16(10):5389-97. PubMed ID: 18440235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
